Medical experts favour highly-regulated, highly-repeatable therapeutic options when it comes to cannabis, which is something producers have been struggling with for a while.
Canopy Health Innovations, the partly-owned biopharmaceutical research and development arm of Canopy Growth Corporation just announced that it had filed eight provisional US patents for the delivery and application of cannabis and cannabinoid-based therapeutics for specific indications.
Canopy Health and its affiliates are collaborating, along with respected world-class academic researchers and clinicians, and some leading research organizations, are developing and registering breakthrough cannabis products that target disease areas with substantial medical needs. Specifically, the following.
- Amyotrophic Lateral Sclerosis (also known as ALS, Lou Gehrig’s disease)
- Cognitive enhancement
- Opioid sparing, pain management, and addiction
- Addiction and smoking cessation
- Plus, some updates to previous Insomnia-related patent applications
With additional patents for methods of cannabis-based composition delivery, the total number of US provisional patent filings comes to thirty-nine. Some of these include licenses for both humans and animal products, though the Canopy Animal Health affiliate, and joint-ventures with Beckley Canopy Therapeutics.
Although cannabis is not presently federally legal in the U.S., it is still the most common “first to file” jurisdiction for intellectual property generation and future protection for cannabis medicines and cannabinoid activities. Canopy Health starts by filing provisional cannabis patents in the U.S. to create a priority date and allow for future filings in other selected jurisdictions, including Canada.
With enough of a body of knowledge around cannabinoid medicine, the team behind Canopy Health believe it could become more mainstream healthcare.